🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

BRIEF-Hedgepath Pharmaceuticals, Mayne Pharma Enter Updated Collaboration & Funding Agreements

Published 18/12/2018, 09:13 am
© Reuters.  BRIEF-Hedgepath Pharmaceuticals, Mayne Pharma Enter Updated Collaboration & Funding Agreements
INTI
-

Dec 17 (Reuters) - HedgePath Pharmaceuticals Inc HPPI.PK :

* HEDGEPATH PHARMACEUTICALS AND MAYNE PHARMA ENTER INTO UPDATED COLLABORATION AND FUNDING AGREEMENTS

* UNDER NEW SLA, CO WILL ASSUME CONTROL OF REGULATORY AND CLINICAL DEVELOPMENT PROGRAM FOR SUBA-ITRACONAZOLE

* TO TRANSFER SUBA-ITRACONAZOLE BCCNS CLINICAL PROGRAM TO MAYNE IN CONSIDERATION OF UP TO $5 MILLION IN NEW FUNDING FROM MAYNE

* WILL IMMEDIATELY ASSUME RESPONSIBILITY FOR ALL FUTURE SUBA-ITRACONAZOLE BCCNS-RELATED EXPENSES

* WITH NEW FUNDING, CO TO MOVE TOWARDS IND FILING DURING 2019 & RECRUITMENT TO INITIATE HUMAN TRIALS FOR SUBA-ITRACONAZOLE PROSTATE

* CO TO RECEIVE 9% ROYALTY ON FUTURE NET SALES OF SUBA-ITRACONAZOLE BCCNS IN U.S.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.